Key Points
- Carlsmed COO Jeffrey Bertolini sold 747 shares at $15.15, for about $11,317, reducing his ownership by 3.21%; he retained 22,489 shares.
- Bertolini also made several stock sales in recent months, including 243 shares on October 30 and 747 shares on October 5.
- Analysts maintain a Moderate Buy consensus, with an average price target of $19.50; the company recently reported quarterly revenue of $18.94 million and an EPS loss of $0.39.
Carlsmed, Inc. (NASDAQ:CARL - Get Free Report) COO Jeffrey Bertolini sold 747 shares of the company's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $15.15, for a total transaction of $11,317.05. Following the transaction, the chief operating officer directly owned 22,489 shares in the company, valued at approximately $340,708.35. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Jeffrey Bertolini also recently made the following trade(s):
- On Friday, October 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $15.80, for a total transaction of $3,839.40.
- On Monday, October 5th, Jeffrey Bertolini sold 747 shares of Carlsmed stock. The shares were sold at an average price of $14.39, for a total transaction of $10,749.33.
- On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The stock was sold at an average price of $13.99, for a total transaction of $3,399.57.
Carlsmed Stock Performance
CARL stock opened at $16.09 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The company's 50-day moving average price is $14.98 and its 200 day moving average price is $12.47. Carlsmed, Inc. has a 52 week low of $8.50 and a 52 week high of $17.23.
Carlsmed (NASDAQ:CARL - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The company had revenue of $18.94 million during the quarter. On average, equities analysts expect that Carlsmed, Inc. will post -1.50 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Zevenbergen Capital Investments LLC boosted its position in shares of Carlsmed by 50.4% in the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company's stock worth $252,000 after acquiring an additional 6,000 shares during the last quarter. Bank of America Corp DE purchased a new position in Carlsmed during the second quarter worth approximately $108,000. Jupiter Topco LLC acquired a new position in shares of Carlsmed in the 2nd quarter valued at $12,992,000. Parkman Healthcare Partners LLC acquired a new position in shares of Carlsmed in the 2nd quarter valued at $6,200,000. Finally, Alpine Woods Capital Investors LLC purchased a new stake in shares of Carlsmed during the 2nd quarter valued at $161,000.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. BTIG Research upped their target price on shares of Carlsmed from $23.00 to $24.00 and gave the company a "buy" rating in a report on Monday, October 12th. Weiss Ratings raised Carlsmed from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded Carlsmed from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Finally, Truist Financial lifted their price objective on Carlsmed from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $19.50.
Get Our Latest Analysis on CARL
Carlsmed Company Profile
(
Get Free Report)
Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.
Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed's technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.
Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
